Published in Curr Opin Pediatr on August 01, 2016
Clinical Trial of Simvastatin to Treat Generalized Vitiligo | NCT01517893
Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin (2017) 0.75
Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets. BMC Genomics (2017) 0.75
CD4 T cells: fates, functions, and faults. Blood (2008) 7.03
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med (2014) 3.54
Alopecia areata. N Engl J Med (2012) 2.56
Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol (2010) 2.48
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol (2015) 2.02
Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol (2012) 2.02
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol (2014) 1.73
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50
Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun (2015) 1.32
Vitiligo. Lancet (2015) 1.27
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol (2015) 1.20
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine (2015) 1.15
Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol (2011) 1.15
What causes alopecia areata? Exp Dermatol (2013) 1.14
Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol (2011) 1.04
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol (2014) 1.03
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol (2015) 1.01
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol (2015) 1.00
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis (2004) 0.99
Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol (2013) 0.97
Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol (2014) 0.95
Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse. J Invest Dermatol (2012) 0.90
Oxidative stress in alopecia areata: a case-control study. Am J Clin Dermatol (2014) 0.88
The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev (2014) 0.87
Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol (2016) 0.85
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol (2015) 0.85
Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatol (2016) 0.83
Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol (2015) 0.82
Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol (2015) 0.81
Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med (2015) 0.81
Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev (2016) 0.80
Vitiligo and alopecia areata: apples and oranges? Exp Dermatol (2013) 0.79
Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res (2014) 0.79
Oxidative Stress-Induced Chemokine Production Mediates CD8(+) T Cell Skin Trafficking in Vitiligo. J Investig Dermatol Symp Proc (2015) 0.79
Use of permanent hair dyes and risk of vitiligo in women. Pigment Cell Melanoma Res (2015) 0.79
The distribution pattern of segmental vitiligo: clues for somatic mosaicism. Br J Dermatol (2012) 0.78
Oxidative stress and alopecia areata. J Med Life (2015) 0.78
Investigation of oxidative stress in patients with alopecia areata and its relationship with disease severity, duration, recurrence and pattern. Clin Exp Dermatol (2014) 0.78
Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? J Dermatol Sci (2015) 0.77
The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata. Exp Dermatol (2014) 0.77
Evidence-based management of vitiligo: summary of a Cochrane systematic review. Br J Dermatol (2016) 0.77
Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata. J Invest Dermatol (2016) 0.76
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50
A network of high-mobility group box transcription factors programs innate interleukin-17 production. Immunity (2013) 1.12
Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol (2013) 0.97
EGR-2 is not required for in vivo CD4 T cell mediated immune responses. PLoS One (2010) 0.85
Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell Immunol (2009) 0.79
Melanocytes in psoriasis: convicted culprit or bullied bystander? Pigment Cell Melanoma Res (2016) 0.75
Cavitation rheology as a potential method for in vivo assessment of skin biomechanics. Plast Reconstr Surg (2013) 0.75
IFN-γ in Vitiligo, Is It the Fuel or the Fire? Acta Derm Venereol (2015) 0.75